Potential Drugs

I. K. MANGION,* R. T. RUCK, N. RIVERA, M. A. HUFFMAN, M. SHEVLIN (MERCK AND CO., INC., RAHWAY, USA)

A Concise Synthesis of a β -Lactamase Inhibitor *Org. Lett.* **2011**, *13*, 5480–5483.

Synthesis of MK-7655

Significance: MK-7655 is a potent β -lactamase inhibitor. It is in clinical trials for the treatment of bacterial infections in conjunction with β -lactam antibiotics. The bicyclic urea is highly reactive and a major challenge was to find conditions for its formation and preservation during the construction of the aminoxy sulfate. This work features the first practical application of the N–H insertion of a sulfoxonium ylide ($\mathbf{D} \to \mathbf{E}$) in a complex synthesis.

 $\begin{array}{lll} \textbf{SYNFACTS Contributors:} & Philip Kocienski \\ Synfacts & 2012, 8(1), 0001 & Published online: 19.12.2011 \\ \textbf{D0I:} & 10.1055/s-0031-1289917; & \textbf{Reg-No.:} & K07011SF \\ \end{array}$

Comment: The synthesis depicted delivered multikilogram quantities of API in twelve steps and 10% overall yield. MK-7655 is only stable in the pH range of 4–8; therefore, removal of the Boc group in the final step cannot be achieved under the usual acidic conditions. After extensive experiments, 1.4 equivalents of HBF₄·OEt₂ in trifluoroethanol successfully removed the Boc group.

MK-7655

Key words

β-lactamase inhibitors

iridium-catalyzed N–H insertion

sulfoxonium ylides

